Elisa Tavanti

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.

Journal: Frontiers in oncology
Published: December 19, 2019

Crosstalk Between Adipokines and Paraoxonase 1: A New Potential Axis Linking Oxidative Stress and Inflammation.

Crosstalk Between Adipokines and Paraoxonase 1: A New Potential Axis Linking Oxidative Stress and Inflammation.

Journal: Antioxidants (Basel, Switzerland)
Published: July 08, 2019

Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?

Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?

Journal: Expert review of molecular diagnostics
Published: October 17, 2018

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.

Journal: Cellular and molecular life sciences : CMLS
Published: April 30, 2018

Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?

Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?

Journal: Future oncology (London, England)
Published: February 11, 2017

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Journal: Pharmacogenomics
Published: November 25, 2016

Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.

Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.

Journal: Expert opinion on drug metabolism & toxicology
Published: October 21, 2016

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.

Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.

Journal: PloS one
Published: June 29, 2016

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.

Journal: Oncotarget
Published: June 01, 2016

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.

Journal: Current cancer drug targets
Published: August 11, 2015

Advances in emerging drugs for osteosarcoma.

Advances in emerging drugs for osteosarcoma.

Journal: Expert opinion on emerging drugs
Published: May 30, 2015

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Journal: Investigational new drugs
Published: July 08, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026